The combination of two different biotherapies (interferon alfa-2b and tremelimumab) may be beneficial for patients with inoperable melanoma, revealed by researchers in US.
The study by University of Pittsburgh Cancer Institute (UPCI) presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Melanoma is the most serious type of skin cancer. It begins in skin cells called melanocytes. If the skin receives too much ultraviolet light, the melanocytes may begin to grow abnormally and become cancerous. This condition is called melanoma. The first sign of melanoma is often a change in the size, shape, or color of a mole. But melanoma can also appear on the body as a new mole.
Researchers in the melanoma and skin cancer program at UPCI combined two biotherapies treatments that stimulate the immune system to fight cancer and found the results promising in terms of anti-tumor effects and tolerable in terms of toxicity. High-dose interferon alfa-2b, a standard treatment for metastatic skin cancer, and tremelimumab,…